Iyer Radhakrishnan P, Padmanabhan Seetharamaiyer, Zhang Guangrong, Morrey John D, Korba Brent E
Spring Bank Technologies Inc, Milford, MA 01757, USA.
Curr Opin Pharmacol. 2005 Oct;5(5):520-8. doi: 10.1016/j.coph.2005.04.019.
During the past decade, nucleotide analogs have emerged as novel antiviral agents against hepatitis B virus. Adefovir dipivoxil, a prototype phosphonate analog, has been approved for chronic hepatitis B virus therapy, and additional phosphonate analogs and di- and tri-nucleotides are under development. Several innovative prodrug derivatizations have also been reported to improve the oral bioavailability of nucleotide analogs, which usually carry a negative charge.
在过去十年中，核苷酸类似物已成为抗乙型肝炎病毒的新型抗病毒药物。阿德福韦酯，一种原型膦酸酯类似物，已被批准用于慢性乙型肝炎病毒治疗，其他膦酸酯类似物以及二核苷酸和三核苷酸正在研发中。也有一些创新性的前药衍生化报道，用于提高通常带负电荷的核苷酸类似物的口服生物利用度。
